Almirall submits European MAA for COPD drug
This article was originally published in Scrip
Executive Summary
Following hot on the heels a US filing, Almirall has submitted a marketing authorisation application to the European Medicines Agency (EMA) for its long-acting inhaled antimuscarinic agent, aclidinium bromide, to treat chronic obstructive pulmonary disease (COPD).